• English
    • svenska
  • English 
    • English
    • svenska
  • Login
View Item 
  •   Home
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Neuroscience and Physiology / Inst för neurovetenskap och fysiologi
  • Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi
  • View Item
  •   Home
  • Sahlgrenska Academy / Sahlgrenska akademin
  • Institute of Neuroscience and Physiology / Inst för neurovetenskap och fysiologi
  • Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Acquired epilepsy in Multiple sclerosis: a nationwide register-based investigation into prognosis and treatment

Abstract
The prevalence of epilepsy in persons with multiple sclerosis (MS) is thrice that of the general population. The association between epilepsy and MS prognosis and its management are however largely unknown. The prevalence of concomitant MS and epilepsy is low, making recruitment of sufficient numbers of patients for single-centre studies difficult. To circumvent this, we cross-referenced the Swedish MS register (SMSreg), which covers at least 80% of prevalent MS cases, with a series of other national registers, making a cohort of up to 370 MS patients with epilepsy available for our studies. This thesis addresses clinically pertinent questions on diagnosis, prognostic impact and treatment of epilepsy in MS. In a first-ever evaluation, we found the 10-year risk of epilepsy following a first unprovoked seizure in MS to be 51.4% (95% CI 44 – 58.9%). Hence, a single seizure in MS is not sufficient for epilepsy diagnosis as it does not exceed the diagnostic threshold (60%) (Paper I). In assessing the prognostic impact of epilepsy, we found epilepsy to be associated with at least fourfold increased mortality, although seizure-related deaths were rare. Epilepsy was not associated with an increased risk of conversion to secondary progressive MS (Paper II). Regarding treatment of epilepsy in MS, we discovered carbamazepine to be the most prescribed antiseizure medication at treatment initiation, although retention tended to be higher with lamotrigine (Paper III). Lastly, we tested the hypothesis whether the introduction of disease modifying treatments for MS has affected the incidence of epilepsy in MS. We could not confirm this, but instead found a steady increase in epilepsy prevalence between 1991 – 2018 (Paper IV). In conclusion, we confirm a negative prognostic association between epilepsy and MS and offer novel insights into diagnosis and treatment of epilepsy in MS. We also demonstrate the feasibility and necessity of using a register-based approach to study a relatively rare form of acquired epilepsy.
Parts of work
I. Mahamud Z, Burman J, Zelano J. Risk of epilepsy after a single seizure in multiple sclerosis. European journal of neurology 2018;25:854-860. http://doi.org/10.1111/ene.13618
 
II. Mahamud Z, Burman J, Zelano J. Prognostic impact of epilepsy in multiple sclerosis. Mult Scler Relat Disord 2020;38:101497. http://doi.org/10.1016/j.msard.2019.101497
 
III. Mahamud Z, Håkansson S, Burman J, Zelano J. Retention of antiseizure medications for epilepsy in multiple sclerosis: A retrospective observational study. Epilepsy Behav 2021;121:108034. http://doi.org/10.1016/j.yebeh.2021.108034
 
IV. Mahamud Z, Burman J, Zelano J. Temporal trends of epilepsy in multiple sclerosis. Acta neurologica Scandinavica 2022. http://doi.org/10.1111/ane.13671
 
Degree
Doctor of Philosophy (Medicine)
University
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Neuroscience and Physiology. Department of Clinical Neuroscience
Disputation
Tisdagen den 13 december 2022, kl. 13.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg. https://gu-se.zoom.us/j/63217947176?pwd=V1Z1MVpmZVFEVFFpWXJqcDdlZm9KZz09
Date of defence
2022-12-13
E-mail
zamzam.mahamud@neuro.gu.se
mahamud.zamzam@gmail.com
URI
https://hdl.handle.net/2077/72048
Collections
  • Doctoral Theses / Doktorsavhandlingar Institutionen för neurovetenskap och fysiologi
View/Open
Abstract (105.1Kb)
Thesis frame (1008.Kb)
Cover (237.0Kb)
Date
2022-11-22
Author
Mahamud, Zamzam
Keywords
Multiple sclerosis
epilepsy
seizure
diagnosis
mortality
antiseizure medication
prevalence
incidence
Publication type
Doctoral thesis
ISBN
978-91-8069-069-0 (tryckt)
978-91-8069-070-6 (PDF)
Language
eng
Metadata
Show full item record

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

DSpace software copyright © 2002-2016  DuraSpace
Contact Us | Send Feedback
Theme by 
Atmire NV